Overview

To Evaluate Patient Preference of Movantik and Polyethylene Glycol 3350 for Opioid Induced Constipation

Status:
Completed
Trial end date:
2017-08-23
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine whether patients with opioid induced constipation prefer treatment with naloxegol (Movantik) or with Polyethylene Glycol 3350.
Phase:
Phase 4
Details
Lead Sponsor:
AstraZeneca
Collaborator:
QuintilesIMS, Inc.
Treatments:
Analgesics, Opioid
Naloxegol
Polyethylene glycol 3350